GO:1902563 regulation of neutrophil activation: Immune Signaling Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1902563 (regulation of neutrophil activation) is a biological process term defined as any process that modulates the frequency, rate or extent of neutrophil activation.
• Neutrophil activation is controlled at multiple levels, including Toll-like receptor signaling, purinergic signaling, transcriptional regulation, and epitranscriptomic mRNA methylation [1,3,6].
• Key regulators include METTL3, KLF2, TLR4, EGFR, CEBPβ, and PGLYRP1, which modulate neutrophil effector functions such as NETosis and cytokine release [1,2,7].
• Dysregulated regulation of neutrophil activation contributes to acute lung injury, cardiac hypertrophy and heart failure, Kawasaki disease, MIS-C, and Behçet's disease [2,4,5,8].
• Pharmacological blockade of phosphodiesterase 4 reduces neutrophil activation in Behçet's disease, demonstrating that this process is therapeutically tractable.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable causal dissection of regulators within this GO term [1,2,7].
Description
GO:1902563, regulation of neutrophil activation, is a Gene Ontology biological process term that encompasses any process modulating the frequency, rate, or extent of neutrophil activation. Neutrophils are the most abundant circulating leukocytes and act as first responders to infection and injury; their activation state must be tightly controlled to balance antimicrobial defense against host tissue damage [3,6]. The regulatory inputs converge on surface receptors, intracellular signaling cascades, and transcriptional or post-transcriptional programs that determine whether a neutrophil remains quiescent or acquires effector functions such as degranulation, oxidative burst, and NETosis [1,7]. Research into this term matters because inappropriate neutrophil activation is a shared feature of diverse inflammatory and cardiovascular disorders. For example, KLF2 regulates neutrophil activation and thrombosis in cardiac hypertrophy and heart failure progression, while single-cell meta-analysis has identified shared neutrophil activation signatures in Kawasaki disease and multisystem inflammatory syndrome in children. In Behçet's disease, phosphodiesterase 4 blockade reduces neutrophil activation, linking the pathway to a specific therapeutic strategy. Mechanistically, regulation of neutrophil activation integrates Toll-like receptor signaling, purinergic regulation, and epigenetic or epitranscriptomic control. METTL3-mediated m6A mRNA methylation regulates neutrophil activation through targeting TLR4 signaling, and purinergic signaling fine-tunes neutrophil function through nucleotide receptors. EGFR orchestrates neutrophil activation and NETosis via CEBPβ-dependent PGLYRP1 induction, providing a direct transcriptional axis. These findings position GO:1902563 as a convergence point for inflammatory signaling and a target-rich area for functional genomics.
regulation of neutrophil activation At A Glance
| GO ID | GO:1902563 |
|---|---|
| GO term | regulation of neutrophil activation |
| Ontology | biological_process |
| Synonym | none |
| Major function | Modulates the frequency, rate or extent of neutrophil activation |
| Related processes | Toll-like receptor signaling, purinergic signaling, NETosis, cytokine production |
| Key regulators | METTL3, KLF2, TLR4, EGFR, CEBPβ, PGLYRP1 |
| Disease relevance | Acute lung injury, heart failure, Kawasaki disease, MIS-C, Behçet's disease |
What Is GO:1902563?
According to the QuickGO definition, GO:1902563 (regulation of neutrophil activation) refers to any process that modulates the frequency, rate or extent of neutrophil activation. In practical terms, this term captures all molecular and cellular events that either promote or suppress the transition of a neutrophil from a resting state to an activated state, including changes in receptor signaling, gene expression, and effector functions [1,3,6].
Why Is regulation of neutrophil activation Important in Cell Biology?
Understanding GO:1902563 is important because neutrophil activation is a double-edged sword: it is essential for pathogen clearance but can drive tissue injury when dysregulated [3,8]. The regulatory mechanisms within this term determine the threshold, duration, and intensity of neutrophil responses, and their perturbation is linked to acute lung injury, cardiac hypertrophy, heart failure, Kawasaki disease, MIS-C, and Behçet's disease [2,4,5,8]. Moreover, pharmacological or genetic modulation of these regulators can reduce pathological neutrophil activation, as shown by phosphodiesterase 4 blockade in Behçet's disease. Thus, GO:1902563 provides a framework for identifying therapeutic targets and biomarkers across inflammatory and cardiovascular diseases.
• Defines the molecular checkpoints that prevent inappropriate neutrophil activation in healthy tissues [3,6].
• Links Toll-like receptor and purinergic signaling to neutrophil effector functions [3,6].
• Explains how epitranscriptomic modifications such as m6A methylation control neutrophil activation via TLR4.
• Provides a mechanistic basis for thrombosis in cardiac hypertrophy and heart failure through KLF2.
• Underlies shared inflammatory signatures in Kawasaki disease and MIS-C.
• Identifies phosphodiesterase 4 as a druggable node in Behçet's disease.
• Highlights EGFR-CEBPβ-PGLYRP1 as a transcriptional axis driving NETosis.
• Supports development of biomarkers for acute lung injury and systemic inflammatory diseases [4,8].
• Enables CRISPR-based functional genomics to causally test regulators in immune cells [1,2,7].
• Informs combination therapies that target neutrophil activation without compromising host defense [5,6].
What Happens During regulation of neutrophil activation?
Receptor-level initiation and Toll-like receptor signaling
In simple terms: Neutrophils first sense danger signals through surface receptors, which decide whether they become activated.
Regulation of neutrophil activation begins with receptor engagement by pathogen-associated or damage-associated molecular patterns. Toll-like receptors play a central role in regulating neutrophil migration, activation, and apoptosis, thereby setting the threshold for subsequent effector responses. Purinergic receptors for extracellular nucleotides also modulate neutrophil function, providing an additional layer of control over activation. These receptor inputs are integrated into intracellular signaling cascades that determine the magnitude and duration of the activated state.
Epitranscriptomic control via m6A mRNA methylation
In simple terms: Chemical marks on mRNA can turn neutrophil activation up or down by changing how much protein is made.
METTL3-mediated m6A mRNA methylation regulates neutrophil activation through targeting TLR4 signaling. This epitranscriptomic modification affects the stability or translation of key transcripts, thereby tuning the responsiveness of neutrophils to activating stimuli. The discovery that m6A methylation controls TLR4 signaling places RNA modification upstream of receptor-driven activation programs.
Transcriptional regulation by KLF2 and CEBPβ
In simple terms: Transcription factors act as master switches that turn neutrophil activation genes on or off.
KLF2 regulates neutrophil activation and thrombosis in cardiac hypertrophy and heart failure progression, indicating that this transcription factor suppresses pathological activation in the heart. In a separate axis, EGFR orchestrates neutrophil activation and NETosis via CEBPβ-dependent PGLYRP1 induction, showing that CEBPβ drives a transcriptional program leading to NET formation. Together, these transcription factors define opposing or context-dependent arms of regulation within GO:1902563.
Effector outputs: NETosis, degranulation, and cytokine release
In simple terms: Once activated, neutrophils release web-like structures, granules, and cytokines to fight infection or cause damage.
The ultimate outputs of neutrophil activation include NETosis, degranulation, and cytokine production. EGFR-driven, CEBPβ-dependent PGLYRP1 induction promotes NETosis, directly linking a regulatory axis to a specific effector mechanism. In acute lung injury, regulation of neutrophil activation determines the extent of pulmonary damage, with excessive activation leading to tissue injury. These effector outputs are the measurable endpoints that define whether regulation of neutrophil activation is protective or pathological.
Pharmacological and disease-context modulation
In simple terms: Drugs and disease states can shift the balance of neutrophil activation up or down.
Phosphodiesterase 4 blockade reduces neutrophil activation in Behçet's disease, demonstrating that the process can be therapeutically suppressed. Single-cell meta-analysis of Kawasaki disease and MIS-C reveals shared immunological drivers of neutrophil activation, suggesting common regulatory nodes across inflammatory syndromes. In cardiac hypertrophy and heart failure, KLF2-dependent regulation of neutrophil activation influences thrombosis, connecting this GO term to cardiovascular pathology.
Key Genes Involved in GO:1902563 regulation of neutrophil activation
The following genes and proteins have been experimentally implicated in the regulation of neutrophil activation (GO:1902563).
| Gene | Major Role | Research Relevance |
|---|---|---|
| METTL3 | m6A mRNA methyltransferase that regulates neutrophil activation via TLR4 signaling | Epitranscriptomic control of neutrophil activation |
| TLR4 | Toll-like receptor mediating neutrophil activation in response to LPS | Target of METTL3-dependent regulation |
| KLF2 | Transcription factor that regulates neutrophil activation and thrombosis | Cardiac hypertrophy and heart failure progression |
| P2RY12 | Purinergic receptor involved in neutrophil function | Purinergic regulation of neutrophil activation |
| ADORA2A | Adenosine receptor modulating neutrophil activation | Purinergic regulation of neutrophil function |
| PDE4 | Phosphodiesterase that modulates cAMP levels in neutrophils | Target of blockade in Behçet's disease |
| TLR2 | Toll-like receptor regulating neutrophil migration and activation | Innate immune regulation of neutrophils |
| TLR5 | Toll-like receptor recognizing flagellin | Regulation of neutrophil activation and apoptosis |
| EGFR | Receptor tyrosine kinase orchestrating neutrophil activation and NETosis | CEBPβ-dependent PGLYRP1 induction |
| CEBPβ | Transcription factor downstream of EGFR | Drives PGLYRP1 expression and NETosis |
| PGLYRP1 | Peptidoglycan recognition protein induced by CEBPβ | Mediates NETosis in activated neutrophils |
| CXCR2 | Chemokine receptor mediating neutrophil recruitment and activation | Acute lung injury models |
| ITGB2 | Integrin subunit involved in neutrophil adhesion and activation | Acute lung injury and inflammation |
| SELPLG | Selectin ligand mediating neutrophil rolling | Acute lung injury and vascular inflammation |
| NLRP3 | Inflammasome component contributing to neutrophil activation | Inflammatory disease models |
| IL1B | Cytokine produced by activated neutrophils | Kawasaki disease and MIS-C |
| TNF | Cytokine amplifying neutrophil activation | Behçet's disease and systemic inflammation |
How Is regulation of neutrophil activation Regulated?
Regulation of neutrophil activation (GO:1902563) is itself controlled by multiple upstream inputs. Toll-like receptor signaling sets the initial threshold for activation and apoptosis, while purinergic signaling provides a second layer of control through extracellular nucleotides. Epitranscriptomic regulation by METTL3-dependent m6A methylation modulates TLR4 signaling, thereby influencing the sensitivity of neutrophils to activating cues. Transcription factors such as KLF2 and CEBPβ act as downstream integrators that either suppress or promote activation programs [2,7]. Pharmacologically, phosphodiesterase 4 blockade reduces neutrophil activation, indicating that cAMP-dependent pathways are part of the regulatory network. These layers ensure that neutrophil activation is context-dependent and reversible.
regulation of neutrophil activation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KLF2 | Cardiac hypertrophy and heart failure | Knockout and overexpression in cardiomyocyte-neutrophil co-culture |
| METTL3 | Inflammatory signaling via TLR4 | Knockout and point mutation in neutrophil-like cell lines |
| PDE4 | Behçet's disease | Pharmacological inhibition and knockout in primary neutrophils |
| EGFR | NETosis and inflammatory tissue damage | Knockout and knock-in of CEBPβ binding site |
| TLR4 | Acute lung injury and sepsis | Knockout and point mutation in murine models |
Cardiovascular disease: cardiac hypertrophy and heart failure
KLF2 regulates neutrophil activation and thrombosis in cardiac hypertrophy and heart failure progression. Dysregulated neutrophil activation in this context promotes thrombotic complications, linking GO:1902563 to cardiovascular morbidity. Targeting KLF2-dependent pathways may reduce thrombosis without broadly immunosuppressing patients.
Inflammatory syndromes: Kawasaki disease and MIS-C
Single-cell meta-analysis of neutrophil activation in Kawasaki disease and MIS-C reveals shared immunological drivers, suggesting that common regulatory nodes within GO:1902563 underlie both conditions. These findings support the development of biomarkers and therapies that target neutrophil activation across pediatric inflammatory syndromes.
Autoinflammatory disease: Behçet's disease
Reduction of neutrophil activation by phosphodiesterase 4 blockade in Behçet's disease demonstrates that pharmacological inhibition of specific regulators within GO:1902563 can produce clinical benefit. This provides proof of concept that neutrophil activation is a modifiable therapeutic target in autoinflammatory disease.
Acute lung injury and pulmonary inflammation
Regulation of neutrophil activation in acute lung injury determines the balance between pathogen clearance and tissue damage. Excessive or prolonged activation leads to alveolar injury, whereas insufficient activation impairs host defense. Understanding the regulatory checkpoints within GO:1902563 is therefore critical for developing lung-protective therapies.
From regulation of neutrophil activation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is METTL3 required for neutrophil activation via TLR4? | METTL3 knockout in neutrophil-like cells |
| Does KLF2 suppress neutrophil activation in heart failure? | KLF2 knockout and overexpression in cardiac hypertrophy models |
| Does PDE4 inhibition reduce neutrophil activation? | PDE4 knockout and pharmacological blockade in Behçet's disease models |
| Does EGFR-driven CEBPβ activation induce NETosis? | EGFR knockout and CEBPβ point mutation |
| Which purinergic receptors regulate neutrophil activation? | Knockout of P2RY12 and ADORA2A in primary neutrophils |
| What transcriptional programs define activated neutrophils? | Tagged knock-in of CEBPβ and RNA-seq |
How to Study the regulation of neutrophil activation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcriptome changes | Identify activation-induced gene programs |
| Single-cell RNA-seq | Cell-type-specific expression | Dissect neutrophil heterogeneity in inflammatory diseases |
| MeRIP-seq | m6A methylation sites on mRNA | Map METTL3 targets such as TLR4 |
| Immunofluorescence | NETosis and extracellular DNA structures | Validate EGFR-CEBPβ-PGLYRP1 axis |
| Flow cytometry | Surface activation markers | Quantify neutrophil activation states |
| Western blot | Protein expression and phosphorylation | Confirm signaling changes after perturbation |
| CRISPR knockout | Loss-of-function phenotypes | Test causal role of candidate regulators [1,2,7] |
| Pharmacological inhibition | Druggability of regulatory nodes | Evaluate PDE4 blockade in Behçet's disease |
Transcriptomic and single-cell profiling
RNA-seq and single-cell RNA-seq can identify gene expression programs associated with neutrophil activation states. Single-cell meta-analysis has been used to reveal shared immunological drivers of neutrophil activation in Kawasaki disease and MIS-C. These methods help define the transcriptional signature of GO:1902563 in patient samples.
Epitranscriptomic mapping
m6A RNA immunoprecipitation and sequencing (MeRIP-seq) can map METTL3-dependent methylation sites on transcripts such as TLR4, linking epitranscriptomic marks to neutrophil activation. This approach identifies direct targets of regulation within GO:1902563.
Functional assays for NETosis and degranulation
NETosis can be quantified by immunofluorescence for extracellular DNA-histone complexes, and degranulation by measuring granule-derived proteins. EGFR-CEBPβ-PGLYRP1-dependent NETosis has been demonstrated using such assays. These functional readouts are essential for validating regulatory mechanisms.
Pharmacological and genetic perturbation
Small-molecule inhibitors such as phosphodiesterase 4 blockers can be used to test whether a regulatory node is druggable. Genetic perturbation by CRISPR knockout or point mutation provides causal evidence for the role of specific genes in GO:1902563 [1,2,7].
How CRISPR Can Be Used to Study GO:1902563 regulation of neutrophil activation
Knockout
CRISPR knockout of METTL3, KLF2, or EGFR can test whether these genes are required for neutrophil activation. For example, METTL3 knockout reduces m6A methylation and impairs TLR4 signaling, directly linking the enzyme to GO:1902563. KLF2 knockout exacerbates neutrophil activation and thrombosis in cardiac hypertrophy models.
Point Mutation
Point mutations can dissect specific residues or regulatory sites. For instance, mutating the CEBPβ binding site in the PGLYRP1 promoter can test whether EGFR-driven NETosis depends on this transcriptional axis. Similarly, point mutations in TLR4 can separate signaling branches controlling neutrophil activation.
Knock-in
Knock-in of tagged alleles, such as fluorescently labeled CEBPβ or PGLYRP1, enables real-time tracking of protein localization and expression during neutrophil activation. Knock-in of reporter constructs can also monitor promoter activity in response to purinergic or Toll-like receptor stimuli [3,6].
Overexpression
Overexpression of KLF2 or METTL3 can test whether increasing their levels suppresses or enhances neutrophil activation. Overexpression of KLF2 may reduce pathological activation in heart failure models, while METTL3 overexpression could amplify TLR4 signaling. These experiments help define the directionality of regulation within GO:1902563.
How EDITGENE Supports regulation of neutrophil activation Research
Researchers studying regulation of neutrophil activation-related genes often need to determine whether a candidate gene is causally involved in modulating neutrophil effector functions. EDITGENE provides CRISPR-based cell model services that enable precise genetic perturbations in immune cell lines and primary cells.
Contact EDITGENE today to design your custom CRISPR model for regulation of neutrophil activation research.
Frequently Asked Questions About regulation of neutrophil activation
What is GO:1902563?
GO:1902563 is the Gene Ontology term for regulation of neutrophil activation, defined as any process that modulates the frequency, rate or extent of neutrophil activation.
What genes are involved in regulation of neutrophil activation?
Key genes include METTL3, TLR4, KLF2, EGFR, CEBPβ, PGLYRP1, and purinergic receptors such as P2RY12 and ADORA2A [1,2,3,7].
How does METTL3 regulate neutrophil activation?
METTL3-mediated m6A mRNA methylation regulates neutrophil activation through targeting TLR4 signaling.
What is the role of KLF2 in neutrophil activation?
KLF2 regulates neutrophil activation and thrombosis in cardiac hypertrophy and heart failure progression.
Which diseases are linked to dysregulated neutrophil activation?
Dysregulated neutrophil activation is linked to acute lung injury, cardiac hypertrophy and heart failure, Kawasaki disease, MIS-C, and Behçet's disease [2,4,5,8].
How can I study regulation of neutrophil activation in the lab?
Common methods include RNA-seq, single-cell RNA-seq, MeRIP-seq, flow cytometry, NETosis assays, and CRISPR knockout or overexpression models [1,4,5,7].
What is the role of Toll-like receptors in neutrophil activation?
Toll-like receptors regulate neutrophil migration, activation, and apoptosis in response to microbial stimuli.
Does phosphodiesterase 4 inhibition affect neutrophil activation?
Yes, phosphodiesterase 4 blockade reduces neutrophil activation in Behçet's disease.
What is the EGFR-CEBPβ-PGLYRP1 axis?
EGFR orchestrates neutrophil activation and NETosis via CEBPβ-dependent PGLYRP1 induction.
How does purinergic signaling regulate neutrophils?
Purinergic regulation of neutrophil function involves extracellular nucleotides and their receptors, which modulate activation and effector responses.
Conclusion
GO:1902563 (regulation of neutrophil activation) is a central biological process that integrates receptor signaling, epitranscriptomic control, and transcriptional programs to determine neutrophil effector functions. Its dysregulation contributes to cardiovascular, inflammatory, and autoinflammatory diseases, and pharmacological or genetic modulation of key nodes such as PDE4, METTL3, KLF2, and EGFR can alter disease outcomes [1,2,5,7]. Continued research using CRISPR-based models and multi-omic profiling will refine our understanding of this process and identify new therapeutic opportunities.
References
- 1. Luo S et al.. 2023. METTL3-mediated m6A mRNA methylation regulates neutrophil activation through targeting TLR4 signaling.. Cell Rep 42(3):112259 PMID: 36920907
- 2. Tang X et al.. 2022. KLF2 regulates neutrophil activation and thrombosis in cardiac hypertrophy and heart failure progression.. J Clin Invest 132(3) PMID: 34793333
- 3. Wang X et al.. 2018. Purinergic Regulation of Neutrophil Function.. Front Immunol 9:399 PMID: 29545806
- 4. Beltran JVB et al.. 2023. Single-Cell Meta-Analysis of Neutrophil Activation in Kawasaki Disease and Multisystem Inflammatory Syndrome in Children Reveals Potential Shared Immunological Drivers.. Circulation 148(22):1778-1796 PMID: 37905415
- 5. Le Joncour A et al.. 2023. Reduction of Neutrophil Activation by Phosphodiesterase 4 Blockade in Behçet's Disease.. Arthritis Rheumatol 75(9):1628-1637 PMID: 36862398
- 6. Sabroe I et al.. 2005. The role of Toll-like receptors in the regulation of neutrophil migration, activation, and apoptosis.. Clin Infect Dis 41 Suppl 7:S421-6 PMID: 16237641
- 7. Liu X et al.. 2026. EGFR orchestrates neutrophil activation and NETosis via CEBPβ-dependent PGLYRP1 induction.. Cell Death Differ 33(7):1369-1383 PMID: 41540251
- 8. Downey GP et al.. 1999. Regulation of neutrophil activation in acute lung injury.. Chest 116(1 Suppl):46S-54S PMID: 10424590
